<DOC>
	<DOCNO>NCT00040027</DOCNO>
	<brief_summary>Chronic hepatitis C infection one leading cause chronic liver disease United States . Approximately one-third patient hepatitis C infection develop cirrhosis liver , lead liver failure liver cancer . The current treatment hepatitis C infection previously untreated patient successful half patient . There establish therapy non-responders . This randomized , double-blinded , multicenter trial determine effectiveness thymosin alpha 1 ( thymalfasin ) 1.6 mg twice weekly plus PEGinterferon alfa-2a 180 ug/wk compare placebo plus PEGinterferon alfa-2a adult chronic hepatitis C without cirrhosis non-responders previous treatment interferon interferon plus ribavirin . The definition non-response require positive HCV RNA test end course least 12 week therapy . Patients receive treatment 12 month , followed-up 6 month end therapy .</brief_summary>
	<brief_title>Thymosin Plus PEG-Interferon Non-Cirrhotic Hepatitis C Patients Who Did Not Respond Interferon Interferon Plus Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<criteria>Inclusion criterion : Signed write informed consent . Age 18 year old . Presence HCV RNA measure qualitative PCR . Nonresponder previous course therapy either IFN alone IFN plus ribavirin . The patient must treat least 12 week . Washout period least 6 month previous therapy IFN alone IFN plus Ribavirin . Liver biopsy consistent chronic hepatitis C within last 12 month treatment start , least 6 month end prior fail therapy . No clinical histological evidence cirrhosis ( METAVIR fibrosis score 0 3 ) . Compensated liver disease prothrombin time prolong less 3 second control , serum albumin stable within normal limit , total bilirubin &lt; 2 mg/dl , history hepatic encephalopathy , esophageal varix ascites . Ultrasound , CT scan , MRI liver within 3 month entry negative HCC . Hematocrit &gt; 30 % , platelet count &gt; 100 x 109/L , WBC &gt; 3 x 109/L , polymorphonuclear white cell count &gt; 1.5 x 109/L . Adequate renal function demonstrate serum creatinine level &lt; 2.0 mg/dL . Normal TSH adequately control thyroid function . If patient woman , use definitive method birth control consultation physician , surgically sterile postmenopausal . Exclusion criterion : Use systemic corticosteroid within 6 month entry . Current use drug know hepatotoxic , drug ( study drug ) know suspected therapeutic activity hepatitis C immunosuppressive drug ( include corticosteroid ) . Any liver disease include hepatitis B , hepatitis delta , alcoholic liver disease , druginduced liver injury , primary biliary cirrhosis , sclerosing cholangitis , autoimmune hepatitis , hemochromatosis , alpha 1antitrypsin deficiency , Wilson 's disease . Alphafetoprotein &gt; 200 ng/mL . Current past diagnosis cirrhosis . Evidence portal hypertension either Doppler ultrasonography gastrointestinal endoscopy . Decompensated liver disease base history hepatic encephalopathy , esophageal varix , ascites . HIV infection diagnose HIV seropositivity confirm Western blot . Concomitant prior history malignancy curatively treat skin cancer surgically cure situ carcinoma cervix . Active infectious process HCV selflimited nature ( eg . TB AIDS ) . Rheumatoid arthritis autoimmune disease ( serum ANA &gt; 1:160 ) . Pregnancy document urine pregnancy test . Alcohol intravenous drug abuse within previous 1 year . Chronic use methadone . Patients poor medical risk nonmalignant systemic disease , opinion investigator , would make unlikely patient could complete protocol . Patients history severe depression require either hospitalization electroshock therapy ; depression associate suicide attempt . Patients significant preexisting cardiac pulmonary disease . Any indication patient would comply condition study protocol . Previous treatment thymosin alpha 1 . Patients know hypersensitivity IFNa . Simultaneous participation another investigational drug study , participation clinical trial involve investigational drug 3 month study entry . Family history intracerebral hemorrhage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>hepatitis C , chronic</keyword>
</DOC>